Podcast Launch: Innovations in Immuno-Oncology
HanchorBio’s new and original podcast series, Innovations in Immuno-Oncology, offer listeners a closer look at the scientific rationale, business strategy, and global licensing perspectives behind next-generation immuno-oncology drug development.
The podcast highlights the core of HanchorBio’s R&D efforts and brings together company leaders and experts to share frontline insights on how clinical data, platform technologies, and licensing validation can unlock broader global market potential. Topics span tumor immunology, product design strategy, international business development, and practical lessons from the path between the laboratory and the global partnering table. Featured guests to date include founder Dr. Scott Liu, Chief Business Officer Dr. YueHua Cong, Vice President of R&D Dr. Chi-Ling Tseng, and Executive Director of CMC Process Development Dr. Vivian Kuo, each offering a distinct perspective on HanchorBio’s innovation strategy in immuno-oncology.
Listen on:
Apple Podcast: https://reurl.cc/Zl6RMl
Spotify: https://reurl.cc/KOayvy
Or search for Innovations in Immuno-Oncology on your preferred podcast platform.
Available Episodes
EP1 | The Game in IO
A discussion on the long-term strategic value of immuno-oncology innovation and next-generation cancer therapeutics.
EP2 | How HanchorBio is Scaling Global Cancer Immunotherapy
A closer look at the HCB101 regional licensing case and HanchorBio’s path
EP3 | Decoding the Business Moat of HCB101
An exploration of the scientific foundations of immuno-oncology and how innovative biologics may reshape cancer treatment strategies.
EP4 | The 1.6% Challenge
An introduction to HanchorBio’s FBDB™ platform and the design principles behind next-generation trifunctional fusion proteins.
EP5 | The 1.6% Frontier
A deep dive into the design logic of HCB301 and the strategic vision behind trifunctional immunotherapy.
EP6 | The CMC Moat
An inside look at why CMC is more than manufacturing, and how process development, quality control, and scalability form a critical moat in turning a promising molecule into a global medicine.
More episodes will be released on an ongoing basis.
Disclaimer
This podcast is intended to help listeners better understand biotechnology industry trends and HanchorBio’s core value through scientific interpretation and business insight. All clinical data referenced are subject to the Company’s official public disclosures. The content does not constitute investment advice of any kind. Any discussion of product potential, technology development, or market opportunity reflects industry experience and professional analysis, and should not be interpreted as a guarantee of future share price, revenue, or profitability.